What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Mektovi (Binimetinib)

Sezzle
Brand

Mektovi (Binimetinib)

Prescription Required

Strength
Qty
15mg

You'll have option to make 4 interest-free payments by credit card once your order is confirmed using Sezzle

We don't have this generic product yet!

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

  • Product Details

    Description

    Your oncologist (cancer doctor) may prescribe Mektovi for managing unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Metastatic melanoma is a type of skin cancer. Mektovi is only for use in combination with encorafenib.

    Functioning as a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activity, Mektovi curbs the growth of cancer cells by preventing the action of these proteins.

    Fact Table

    Formula

    C17H15BrF2N4O3

    License

    US FDA, EMA

    Bioavailability

    ~50%

    Legal status

    Prescription only (?)

    Chemical Name

    (3S)-3-{[(2S)-2-(4-bromo-2-fluorophenyl)-2-(3,3-difluorocyclobutyl)acetyl]amino}-3-methylbutanoic acid

    Elimination half-life

    3.5 hours

    Dosage (Strength)

    15 mg tablets

    Pregnancy

    Not recommended

    Brands

    Mektovi

    Protein binding

    97%

    PubChem CID

    135565536

    MedlinePlus

    a618014

    ChEBI

    134723

    ATC code

    L01XE56

    DrugBank

    DB11995

    KEGG

    D10835

    Routes of administration

    Oral

    Directions

    The recommended dosage entails taking 45 mg orally twice daily in conjunction with encorafenib. Mektovi can be ingested with or without food.

    Patients with a history of liver disease should inform their doctor, as a dosage adjustment to 30 mg twice daily may be necessary.

    It is imperative not to cease or alter the Mektovi dosage without consulting your doctor.

    Ingredients

    The active ingredient in Mektovi is binimetinib.

    Interactions

    There are no significant drug-drug interactions between Mektovi and other medications.

    Cautions

    Patients commencing treatment with a history of heart disease should inform their doctor. Heart function assessments are advisable before starting treatment, after one month, and subsequently every 2-3 months.

    It is crucial to disclose any history of clotting disorders. Caution is warranted for individuals with a history of eye, lung, liver, musculoskeletal, or bleeding disorders.

    Pregnant or individuals planning on becoming pregnant should not take Mektovi.

    Side Effects

    Common adverse reactions include:

    • Abdominal pain
    • Bleeding from anus
    • Bleeding hemorrhoids
    • Cancer
    • Cardiomyopathy
    • Central serous chorioretinopathy
    • Cough (Non-small cell lung cancer)
    • Diarrhea
    • Dyspnea (Non-small cell lung cancer)
    • Fatigue
    • Hemothorax
    • Hematochezia
    • Hemorrhage
    • Intracranial hemorrhage, Fatal
    • Left ventricular cardiac dysfunction
    • Musculoskeletal pain (Non-small cell lung cancer)
    • Nausea
    • Papilloma (Non-small cell lung cancer)
    • Pulmonary embolism
    • Rectal hemorrhage
    • Squamous cell carcinoma of the skin (Non-small cell lung cancer)
    • Thrombosis of retinal vein
    • Uveitis
    • Vomiting
    • Venous thromboembolism

    References

    1. Mektovi [package insert]. Boulder, CO: Array BioPharma; June 2018.


    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14577

  • Product Reviews

Processing..

Please wait while the page is loading. Do not hit refresh or the browser back button to avoid any loss of information.

If you have any questions or concerns, please contact our Customer Service team via the chat option on our website or calling us toll free at: 1-800-891-0844